Company intelligence / Profile preview
Sandoz
- Ownership
- Public · SDZ
- Employees
- ~23000
- Development stage
- Commercial
Overview
Sandoz is one of the world’s largest producers of generic pharmaceuticals and biosimilars. The company has a long history dating back to its founding in Switzerland in the late nineteenth century. It was part of Novartis from the late '90s until spinning out as an independent entity in October 2023. Today it operates globally with a broad portfolio covering small molecule generics and complex biologic medicines such as biosimilars. Recent clinical/commercial highlights include acquiring CIMERLI® (ranibizumab-eqrn) from Coherus BioSciences and entering into agreements to commercialize new biosimilar products like SB17 ustekinumab.
- Therapeutic areas
- Other
- Modalities
- Small moleculesBiosimilars/biologics
- Industry
- Biotech
Drug pipeline
50 assets49 more assets in the full pipeline.
Partnerships
Financials
- Market cap
- $43.3B
- Total revenue
- $11.2B
- Enterprise value
- $48.3B
Beyond the preview
Go deeper on Sandoz.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sandoz.